We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Acute Sleep Loss Triggers Increase in Plasma Levels of Tau Protein in Young Adults

By LabMedica International staff writers
Posted on 20 Jan 2020
Print article
Image: Abnormal accumulation of tau protein in neuronal cell bodies (arrow) and neuronal extensions (arrowhead) in the neocortex of a patient who had died with Alzheimer's disease (Photo courtesy of Wikimedia Commons)
Image: Abnormal accumulation of tau protein in neuronal cell bodies (arrow) and neuronal extensions (arrowhead) in the neocortex of a patient who had died with Alzheimer's disease (Photo courtesy of Wikimedia Commons)
A team of Swedish researchers has found that acute sleep loss results in increased blood levels of t-tau protein, a key biomarker for nervous system disorders such as Alzheimer’s disease.

Previous studies had shown that disrupted sleep increased CSF (cerebrospinal fluid) levels of tau and beta-amyloid (ABeta) and was associated with an increased risk of Alzheimer’s disease (AD). The aim of the current study, conducted by investigators at Uppsala University (Sweden), was to determine whether acute sleep loss altered diurnal profiles of plasma-based AD-associated biomarkers.

The current study involved 15 healthy, normal-weight men with an average age of 22 years. The design of the experiment comprised two phases. For each phase, the subjects were housed in a sleep clinic for two days and nights under a strict meal and activity schedule. Blood samples were collected in the evening and again in the morning. For one phase, participants were allowed an uninterrupted night of sleep both nights. For the other phase, participants were allowed uninterrupted sleep the first night followed by a second night of sleep deprivation.

Plasma levels of total tau (t-tau), ABeta40, ABeta42, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) in the blood samples were assessed using ultrasensitive single molecule array assays or ELISAs,

Results revealed the after sleep deprivation, the subjects had an average 17% increase in tau levels in their blood. In contrast, following a night of interrupted sleep, the subjects had an average increase in tau levels of only 2%. No changes between the sleep conditions were seen for levels of ABeta40, ABeta42, NfL, or GFAP.

"Many of us experience sleep deprivation at some point in our lives due to jet lag, pulling an all-nighter to complete a project, or because of shift work, working overnights. or inconsistent hours," said senior author Dr. Jonathan Cedernaes, a senior researcher at Uppsala University. "Our exploratory study shows that even in young, healthy individuals, missing one night of sleep results in a slight increase in the level of tau in blood. This suggests that over time, similar types of sleep disruption could potentially have detrimental effects."

"It is important to note that while accumulation of tau in the brain is not good, in the context of sleep loss, we do not know what higher levels of tau in blood represent" said Dr. Cedernaes. "When neurons are active, release of tau in the brain is increased. Higher levels in the blood may reflect that these tau proteins are being cleared from the brain or they may reflect an overall elevation of the concentration of tau levels in the brain. Future studies are needed to investigate this further, as well as to determine how long these changes in tau last, and to determine whether changes in tau in blood reflects a mechanism by which recurrent exposure to restricted, disrupted or irregular sleep may increase the risk of dementia. Such studies could provide key insight into whether interventions targeting sleep should begin at an early age to reduce a person's risk of developing dementia or Alzheimer's disease."

The study was published in the January 8, 2020, online edition of the journal Neurology.

Related Links:
Uppsala University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.